Next Article in Journal
Imaging Review of Pediatric Benign Osteocytic Tumors and Latest Updates on Management
Next Article in Special Issue
Resting Heart Rate and Cardiovascular Outcomes during Intensive and Standard Blood Pressure Reduction: An Analysis from SPRINT Trial
Previous Article in Journal
Multiphoton Imaging of Ca2+ Instability in Acute Myocardial Slices from a RyR2R2474S Murine Model of Catecholaminergic Polymorphic Ventricular Tachycardia
Previous Article in Special Issue
Subclinical Cardiac Organ Damage in Patients with Moderate to Severe Psoriasis
Review

The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials

by 1,2,3,†, 2,3,†, 2,3 and 2,3,*
1
School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei 24205, Taiwan
2
Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111045, Taiwan
3
Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111045, Taiwan
*
Author to whom correspondence should be addressed.
Both authors contribute equally to this work.
Academic Editors: Emmanuel Androulakis and Costantino Mancusi
J. Clin. Med. 2021, 10(13), 2824; https://doi.org/10.3390/jcm10132824
Received: 30 May 2021 / Revised: 18 June 2021 / Accepted: 24 June 2021 / Published: 26 June 2021
Background: The management of hypertension remains suboptimal throughout the world. Methods: We performed a random-effects model meta-analysis of randomized controlled trials to determine the effectiveness and safety of sacubitril/valsartan (LCZ696) for the treatment of high arterial pressure. Relevant published articles from PubMed, Cochrane base, and Medline were examined, and the last search date was December 2020. Only published randomized controlled trials and double-blind studies were selected for further analysis. The mean reductions in systolic blood pressure (msSBP) and diastolic blood pressure (msDBP) in the sitting position, as well as the mean reductions in ambulatory systolic blood pressure (maSBP) and ambulatory diastolic blood pressure (maDBP), were assumed as efficacy endpoints. Adverse events (AEs) were considered as safety outcomes. Results: Ten studies with a total of 5931patients were included for analysis. Compared with placebo, LCZ696 had a significant reduction in msSBP (weight mean difference (WMD) = −6.52 mmHg, 95% confidence interval (CI): −8.57 to −4.47; p < 0.001), msDBP (WMD = −3.32 mmHg, 95% CI: −4.57 to −2.07; p < 0.001), maSBP (WMD = −7.08 mmHg, 95% CI: −10.48 to −3.68; p < 0.001), maDBP (WMD = −3.57 mmHg, 95% CI: −5.71 to −1.44, p < 0.001). In subgroup analysis, only 200 mg and 400 mg LCZ696 showed a significant BP reduction. There was no difference in the AE rate between the LCZ696 and placebo groups (WMD = 1.02, 95% CI: 0.83 to 1.27, p = 0.54). Egger’s test revealed a potential publication bias for msSBP (p = 0.025), but no publication bias for other outcomes. Conclusion: LCZ696 may reduce blood pressure more efficaciously than traditional therapy in hypertensive patients without increasing adverse effects. View Full-Text
Keywords: LCZ696; ambulatory systolic blood pressure; hypertension LCZ696; ambulatory systolic blood pressure; hypertension
Show Figures

Figure 1

MDPI and ACS Style

Chua, S.-K.; Lai, W.-T.; Chen, L.-C.; Hung, H.-F. The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2021, 10, 2824. https://doi.org/10.3390/jcm10132824

AMA Style

Chua S-K, Lai W-T, Chen L-C, Hung H-F. The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine. 2021; 10(13):2824. https://doi.org/10.3390/jcm10132824

Chicago/Turabian Style

Chua, Su-Kiat, Wei-Ting Lai, Lung-Ching Chen, and Huei-Fong Hung. 2021. "The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials" Journal of Clinical Medicine 10, no. 13: 2824. https://doi.org/10.3390/jcm10132824

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop